View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 3, 2011

Zalicus Initiates Phase IIb Trial of Rheumatoid Arthritis Drug

Zalicus has initiated a Phase IIb clinical trial of Synavive, a low-dose glucocorticoid to treat rheumatoid arthritis. The 12-week, five-arm, global, double-blind and placebo-controlled SYNERGY trial will evaluate the safety and efficacy of Synavive as a treatment for the signs and sym

By cms admin

Zalicus has initiated a Phase IIb clinical trial of Synavive, a low-dose glucocorticoid to treat rheumatoid arthritis.

The 12-week, five-arm, global, double-blind and placebo-controlled SYNERGY trial will evaluate the safety and efficacy of Synavive as a treatment for the signs and symptoms of rheumatoid arthritis in about 250 subjects.

The results of the clinical trial are expected to be reported in the second half of 2012.

Subjects who complete the core SYNERGY trial will be eligible to participate in a one-year extension study designed to investigate the long-term safety and durability of the drug.

Zalicus has drawn an additional $8.5m from its $20m secured credit facility with Oxford Finance to fund Synavive’s advancement.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology